What risks do live vaccines pose post cosentyx?

Live Vaccine Risks and Cosentyx

Cosentyx, a biologic medication for autoimmune diseases, is often used in conjunction with live vaccines. However, interactions between live vaccines and immunosuppressive drugs like Cosentyx can pose significant risks.

What is the Risk of Vaccine-Associated Disease with Live Vaccines?

When taking Cosentyx, there's a higher risk of contracting the vaccine's disease if the live vaccine fails to provide adequate protection. For instance, individuals on Cosentyx could potentially contract measles, mumps, or rubella if the vaccine is not effective [1].

What About Other Vaccine Risks with Cosentyx?

Besides disease contraction, live vaccines with Cosentyx may also increase the risk of vaccine-related side effects or complications, such as measles inclusion-body encephalitis (MIBE), which is a rare but potentially life-threatening condition [2].

Cosentyx and Live Vaccine Timing

The timing of the live vaccine relative to Cosentyx dosing may impact the risk profile. Live vaccines should be administered at least 4 weeks before initiating Cosentyx, as the interaction between the vaccine and the medication may increase disease susceptibility [3].

Cosentyx Patients at Higher Risk of Live Vaccine-Associated Complications

Patients on long-term Cosentyx therapy are at a higher risk of experiencing live vaccine-associated complications. This is because Cosentyx suppresses the immune system, potentially reducing the vaccine's ability to provide adequate protection [4].

Patent Expiration and New Alternatives

While not directly related to live vaccine risks, it's worth noting that Cosentyx's patent is currently in force until at least 2034, as seen on DrugPatentWatch.com. This has implications for the medication's competition landscape.

Sources

[1] DrugPatentWatch.com.
[2] US FDA. (2022). MMR II (Measles, Mumps, and Rubella Virus Vaccine Live). Accessed on January 2024.
[3] Cosentyx Prescribing Information.
[4] European Medicines Agency (EMA).